Abstract 4021: A seven-lncRNA signature has a good value of prognosis in esophageal squamous cell carcinoma

Abstract

Abstract Background: Long non-coding RNAs (lncRNAs) were used as prognostic biomarkers in many types of cancer. We aimed to recognize a signature that can forecast the prognosis in patients with esophageal squamous cell carcinoma (ESCC). Method: Using a 2520 probe microarray, we retrospectively analysed lncRNAs expression profiles in 141 samples of ESCC and 81 paired non-cancer specimens that were served as the training set from SUN YAT-SEN University Cancer Center (Guangzhou, China) to evaluate the association between the signature and clinical outcomes. We randomly selected 40 paired tumor tissues and adjacent normal tissues from the above samples for the quantitative RT-PCR to ensure the credibility of microarray data. Then we conducted the quantitative RT-PCR in another 103 samples of ESCC to identify the signature. We applied Kaplan-Meier method and log-rank tests to assess the prognostic power of signature with overall survival (OS) and disease-free survival (DFS). Result: Being differently expression between esophageal squamous cell carcinoma tissues and no-cancer specimens, 338 lncRNAs were selected after filtration. A further analysis were conducted that identified a seven-lncRNA signature in the training set. We calculated the risk score according to the signature and classified ESCC patients as high-risk or low-risk group. Patients in high-risk group had shorter overall survival (HR = 3.555, 95%CI 2.195-5.757, p < 0.0001) and disease-free survival (HR 2.537, 95%CI 1.646-3.909, p < 0.0001) when compared with low-risk group in the training set, and we found the same conclusion in the independent set for OS (HR = 2.662, 95%CI 1.588-4.464, p < 0.0001) and DFS (HR 2.389, 95%CI 1.447-3.946, p < 0.0001). The multivariate Cox proportional hazards regression analysis indicated that the signature is an independent factor for predicting survival. Combing the signature and TNM stage was more powerful than TNM stage alone in prognosing outcomes both in the training set (AUC: 0.778 vs 0.681, p = 0.0127) and in the independent set ((AUC: 0.796 vs 0.713, p = 0.0539). Conclusion: The seven-lncRNA signature might win a place as a valuable prognostic factor in patients survival with ESCC and guide a more individual treatment when cooperating with the TNM stage system. Citation Format: Nuoqing Weng. A seven-lncRNA signature has a good value of prognosis in esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4021.